UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-------------
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reportedly): December 15, 2004
OCEAN BIO-CHEM, INC.
(Exact name of registrant as specified in charter)
Florida 2-70197 59-1564329
(State or Other (Commission File Number) (I.R.S. Employer
Jurisdiction of Identification No.)
Incorporation)
4041 S.W. 47 Avenue, Fort Lauderdale, Florida 33314
(Address of principal executive office Zip Code)
(954) 587-6280
Registrant's telephone number,
including area code
Not Applicable
(Former name or former address, if changes since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 4.01 Changes In and Disagreement With Accountants on Accounting and
Financial Disclosure
The Company terminated the services of Berkovits, Lago & Company, LLP
("Former Accountant") as its accountant on December 15, 2004.
(a). The Former Accountant's report did not contain any adverse opinion or
disclaimer of opinion and was not qualified or modified as to uncertainty, audit
scope or accounting principles during the past two years.
The decision to change accountants was recommended and approved by the
Company's independent audit committee.
During the Company's two most recent fiscal years and subsequent interim
periods preceding such dismissal, there were no disagreements with the Former
Accountant on any matter of accounting principles or practices, financial
statement disclosure, or auditing scope or procedure which would have caused the
Former Accountant to make reference to the subject matter of the disagreement in
connection with its report.
The Company has not during the most recent two fiscal years or any
subsequent interim period engaged a new accountant.
The Company has provided its Former Accountant with a copy of this Form 8-K
simultaneously with the filing of this Form 8-K with the Securities and Exchange
Commission ("Commission"). The Company has requested the Former Accountant to
furnish the Company with a letter addressed to the Commission stating whether it
agrees with the statements made by the Company in response to this item 304(A)
and, if not, stating the respects in which it does not agree. The Company shall
file the Former Accountant's letter as an exhibit to a report on Form 8-K when
received.
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: December 16, 2004 Ocean Bio-Chem, Inc.
/s/ Peter G. Dornau
------------------------------------
Peter G. Dornau
Chairman of Board of Directors and
Chief Executive Officer
December 16, 2004
Jesus A. Lago, CPA
Berkovits Lago & Company LLP
8211 West Broward Boulevard
Suite 340
Fort Lauderdale, Florida 33324
Re: Ocean Bio-Chem, Inc.
Dear Mr. Lago:
The Company is filing a Form 8-K with the Securities and Exchange
Commission today with respect to the termination of Berkovits Lago & Company,
LLP as this Company's auditors.
Pursuant to Item 304(a) of Regulation S-K, we are providing you with a copy
of our Form 8-K and request that you furnish us with a letter addressed to the
Securities and Exchange Commission stating whether your firm agrees with the
statements made by the Company in response to Item 304(a) of Regulation S-K and,
if not, stating the respects in which you do not agree. The letter provided by
you shall be filed as an exhibit to a Form 8-K to be filed with the Securities
and Exchange Commission.
Very truly yours,
OCEAN BIO-CHEM, INC.
/s/ Peter G. Dornau
------------------------------------
Peter G. Dornau
Chairman of Board of Directors and
Chief Executive Officer